ArticleScientific reports2025
Revascularization of coronary chronic total occlusion in patients with end stage renal disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic total occlusion (CTO) was frequently observed during coronary angiography. Successful revascularization of chronic total occlusion showed controversial result on long-term survival in previous studies. There is scarce report about long-term outcome of successful recanalization of CTO in patients with end stage renal disease (ESRD) receiving renal replacement therapy. This is a retrospective study conducted in two tertiary medical centers (Taipei and Taichung Veterans General hospitals) in Taiwan. From January 2005 to December 2016, a total of 47,784 patients received coronary angiography in these centers. Among them, 216 patients with ESRD who were found to have CTO lesions during coronary angiography received revascularization. Revascularization was succeeded in 163 patients (75%). Patients were followed up for three years. Successful revascularization was associated with lesser major adverse cardiovascular event (MACE) at 3 year (hazard ratio (HR) 0.518, 95% confidence interval (CI) 0.332-0.810, p = 0.004), better survival at 3 years (HR 0.502, 95% CI 0.314-0.800, p = 0.004) and improved cardiovascular death (HR 0.449, 95% CI 0.223-0.902, p = 0.025). In multivariate analysis, successful revascularization remained independent predictor of three-years MACE (HR 0.588, 95% CI 0.369-0.939, p = 0.026) irrespective of age, gender, serum hemoglobin level, co-morbidities such as peripheral arterial disease and diabetes mellitus and medications such as beta blocker and statin. In patients on renal replacement therapy, successful recanalization of chronic total occlusion reduced MACE at 3 years compared to those failed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.